
France · Computer software startup
Oxyledger is a French health technology startup focused on the digital traceability of implantable medical devices, such as implants and prosthetics.
Funding reportedLast round: Seed
Oxyledger is a French health technology startup focused on the digital traceability of implantable medical devices, such as implants and prosthetics.
Founded in 2019 in Brest, Brittany, the company originated from the CHU de Brest and is currently incubated at IMT Atlantique within the Technopôle Brest-Iroise. Oxyledger operates as a privately held SAS and employs a small team dedicated to enhancing trust among patients, healthcare establishments, and medical device manufacturers. The company offers comprehensive software services for healthcare establishments, covering key aspects of traceability, including logistical tracking, patient safety, financial management, best practices, and scientific data collection. Oxyledger's primary product suite includes OxyFacility for device traceability, OxyKnowledge for sharing medical information, and a digital implant card for patients. Their patented technology is designed to integrate seamlessly with existing hospital information systems, ensuring compliance with regulatory standards. Oxyledger aims to improve clinical follow-up and safety through innovative digital solutions.
Funding, as reported
What they build
Known for
health caresanteprothesestransportation_logisticsdistributionlecture instantanée de codes-barrespartage du savoir médicalgestion des interventions chirurgicalesdmibloc operatoireinformation technology & servicesgs1gestion de la pharmacovigilancesolutions logicielles hospitalièreshospital & health caretraçabilité des dispositifs médicaux
Built with from their website
Google MapsHubSpot Sales HubGoogle Tag ManagerWordPress.orgHREF LangOVHcloudApacheElementorViewport MetaSite Kit
HubspotAll in One SEOHello ElementorPriority HintsGoogle Font APIimagesLoadedMySQLPrimeNG
Add your raise, your deck and your story, and put Oxyledger in front of investors. Or tell us what we have wrong.